Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sunscreen

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Sunscreen. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-001241-14 Sponsor Protocol Number: V00096 CR 201 Start Date*: 2004-11-12
    Sponsor Name:Pierre Fabre Dermatologie represented by Institut de Recherche Pierre Fabre
    Full Title: Efficacy of topic RV3131A-HC3221 in the prevention of polymorphic light eruption
    Medical condition: Polymorphic Light Eruption (PMLE)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004616-31 Sponsor Protocol Number: FR1 Start Date*: 2008-04-11
    Sponsor Name:Universitair Medisch Cemtrum Utrecht
    Full Title: Prevention of neutrophil induced extracellular matrix damage following skin exposure to solar simulating radiation (SSR)
    Medical condition: sunburn (erythema solaris), photoaging (elastosis solaris)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000705 Acute dermatitis due to solar radiation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001519-39 Sponsor Protocol Number: 2008-02-12-1 Start Date*: Information not available in EudraCT
    Sponsor Name:Biologiske Stasjon Drøbak
    Full Title: Efficiency of a jellyfish sting inhibitor sun lotion and protocols for jellyfish sting pain relief
    Medical condition: The degree of pain reduction in test subjects using a specific jellyfish (cnidaria) sting inhibitor and repellent lotion, compared to control subjects being protected by a normal water repellent su...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000253-27 Sponsor Protocol Number: Pelle-926-301E Start Date*: 2020-06-05
    Sponsor Name:PellePharm, Inc.
    Full Title: A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects with Gorlin Syndrome (Basal Cell Nevus Syndrome)
    Medical condition: Basal cell carcinomas (BCCs) in patients with Gorlin syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10004151 Basal cell nevus syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000100-37 Sponsor Protocol Number: V01-126A-202 Start Date*: 2022-01-03
    Sponsor Name:Bausch Health Americas, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Clinical Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel (0.3% adapalene/2.5% BPO), in the Treat...
    Medical condition: Acne Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022678-15 Sponsor Protocol Number: DPSI IDP-110-P4 01 Start Date*: 2011-01-03
    Sponsor Name:Dow Pharmaceutical Sciences, Inc.
    Full Title: A Phase 4 Open-Label Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-110 Gel (ACANYA™ Gel) in Subjects with Acne Vulgaris
    Medical condition: Male or female of any race, at least 18 years of age with a clinical diagnosis of acne vulgaris with a score of 3 (moderate) or 4 (severe) on the Evaluator’s Global Severity Score (EGSS) assessment
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10000519 Acne vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003277-15 Sponsor Protocol Number: 8400-211 Start Date*: 2016-09-02
    Sponsor Name:Idera Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006453-12 Sponsor Protocol Number: NS-304/-03 Start Date*: 2008-07-21
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A multi-centre, multinational, open- label study to evaluate the long-term safety, tolerability and efficacy of selexipag / ACT-293987 (NS-304) in the treatment of pulmonary arterial hypertension i...
    Medical condition: Pulmonary arterial hypertension (PAH) (idiopathic PAH, familial PAH, and PAH associated with collagen disease, corrected congenital vitium or anorexigen use
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) FR (Completed) BE (Completed) GB (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001496-20 Sponsor Protocol Number: SMR3438 Start Date*: 2019-05-14
    Sponsor Name:Katairo GmbH
    Full Title: A multi-national, multi-centre, double-masked, placebo-controlled proof of concept trial to evaluate the safety and efficacy of oral soraprazan in Stargardt disease
    Medical condition: Stargardt Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10062766 Stargardt's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004765-90 Sponsor Protocol Number: DFD03-CD-004 Start Date*: 2016-07-13
    Sponsor Name:Dr. Reddy’s Laboratories, Ltd
    Full Title: A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
    Medical condition: Acne vulgaris
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001179-21 Sponsor Protocol Number: 11-EI-0263 Start Date*: 2018-01-17
    Sponsor Name:The National Eye Institute
    Full Title: A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Branch Retinal Vein Occlusions
    Medical condition: Branch Retinal Vein Occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-001143-12 Sponsor Protocol Number: 11-EI-0264 Start Date*: 2018-01-09
    Sponsor Name:The National Eye Institute
    Full Title: A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Central Retinal Vein Occlusions
    Medical condition: Central Retinal Vein Occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-002113-21 Sponsor Protocol Number: 0822-009 Start Date*: 2005-11-09
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter 16 Week Study to Assess the Effect of Vitamin D3 8400 IU Once Weekly on Body Sway and Neuromuscular Function in Men and Women Over 70 Yea...
    Medical condition: Vitamin D deficiency, unspecified
    Disease: Version SOC Term Classification Code Term Level
    8.0 10047626 LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002845-46 Sponsor Protocol Number: AL-335-604 Start Date*: 2017-02-03
    Sponsor Name:Alios BioPharma, Inc.
    Full Title: A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir, with or without Simeprevir, in Treatment-Naïve Subjects with Genotype ...
    Medical condition: Chronic Hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10076789 Chronic hepatitis C genotype 2 LLT
    20.0 100000004862 10076831 Chronic hepatitis C genotype 3 LLT
    20.0 100000004862 10076786 Chronic hepatitis C genotype 1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000946-24 Sponsor Protocol Number: 15-EI-0202 Start Date*: 2018-01-09
    Sponsor Name:National Eye Institute
    Full Title: Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated with Age-Related Macular Degeneration
    Medical condition: Geographic Atrophy Associated with Age-Related Macular Degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2022-003070-23 Sponsor Protocol Number: CLITRETVER Start Date*: 2023-01-27
    Sponsor Name:Verisfield S.M.S.A.
    Full Title: A multicenter, randomized, double-blind, parallel, three-arm, active- and placebo-controlled therapeutic equivalence for the comparison of clindamycin + tretinoin/Verisfield gel (1+0.025)% with Acn...
    Medical condition: Acne Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024150-10 Sponsor Protocol Number: OPO-ALD-CHF-301 Start Date*: 2011-08-04
    Sponsor Name:Teva Pharmaceutical Industries Ltd.
    Full Title: A-15 week, double-blind, randomized, active-controlled, multicenter study to evaluate the efficacy and safety of Alendronate plus Vitamin D3 in women with osteoporosis
    Medical condition: Treatment of postmenopausal osteoporosis in patients at risk of vitamin D insufficiency.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-004161-13 Sponsor Protocol Number: ZN-c3-006 Start Date*: 2022-04-24
    Sponsor Name:K-Group Beta, Inc.
    Full Title: A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination with Niraparib in Subjects with Platinum-Resistant Ovarian Cancer
    Medical condition: Platinum-resistant Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000344-21 Sponsor Protocol Number: MP1032-CT05 Start Date*: 2021-07-21
    Sponsor Name:MetrioPharm AG
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PROOF-OF-CONCEPT, PHASE IIA STUDY OF MP1032 PLUS STANDARD OF CARE VS STANDARD OF CARE IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH MOD...
    Medical condition: Moderate to severe coronavirus disease 2019 (COVID 19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    23.1 100000004862 10084529 2019 novel coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) ES (Ongoing) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-003736-21 Sponsor Protocol Number: ACE-LY-110 Start Date*: 2017-06-07
    Sponsor Name:Acerta Pharma BV
    Full Title: A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects with Relapsed/Refractory B-cell Malignancies
    Medical condition: Part 1: De novo Diffuse large B-cell lymphoma (DLBCL), Transformed DLBCL and Richter syndrome (RS). Part 2: De novo Germinal center B-cell (GCB) DLBCL and De novo non-GCB DLBCL
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058728 Richter's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:45:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA